Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

England first to approve cervical cancer drug

  • Comment

Women with advanced cervical cancer could live longer after England became the first country in the world to make it routinely available.

Avastin (bevacizumab) is already on the NHS Cancer Drugs Fund list for advanced breast, bowel and ovarian cancer. It has now been added for cervical cancer.

Patients could gain precious extra months of life if their specialist agrees the drug, which cuts the blood supply to tumours, would benefit them.

Robert Music, chief executive of Jo’s Cervical Cancer Trust, said the move represents “very positive” news for women who are diagnosed with cervical cancer at an advanced stage.

Given that the prognosis is often poor “any extra time that can be provided through new drugs becomes extremely valuable”, he explained.

Avastin is not routinely available in other countries, such as the US, as it has not yet received a licence for treating cervical cancer.

The drug has also not yet gone through the usual process for gaining approval from the National Institute for Health and Care Excellence (NICE).

The decision to routinely offer the drug was made in the wake of evidence showing that women with advanced cervical cancer lived, on average, close to an additional four months when taking the drug with chemotherapy, compared with chemotherapy alone.

Professor Peter Clark, chairman of the chemotherapy clinical reference group at NHS England, said: “This new addition to the list demonstrates NHS England’s commitment to achieving maximum benefit to patients from the £200m Cancer Drugs Fund.”

Cancer specialists take a lead in decisions to update the list. The process of doing this “should ensure that patients benefit quickly when new drugs become available that are backed by good evidence from trial data”, he added.

The Cancer Drugs Fund is a list of treatments approved for fast-track use on the NHS before they have gone through the usual regulatory or approval systems.

Cervical cancer is the most common cancer in women under 35 and is on the rise in the UK.

Around 2,900 women are diagnosed every year and the disease causes approximately 1,000 deaths.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs